NAMS · NewAmsterdam Pharma Co N.V.

Track NAMS — free

$21.58 +0.32 (+1.48%) At close · Oct 9

Rebalance outlook locked

Market Cap

$2.58B

119.54M

Volume · Oct 9 1.27M Avg daily vol (3M) 1.36M

Up next

Next earnings call

Nov 4, 2026 Est · unconfirmed · in 3 wks

Latest filing: 10-Q

filed Aug 5, 2026

Q3 2025 earnings call transcript

call held Nov 5, 2025

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$7.12M

Trailing 12 months

Net income (TTM)

−$259.50M

Trailing 12 months

Revenue growth YoY

-80.7%

Year over year

Operating margin

-3,432.2%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-5.6%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$633.85M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+4.1%

Year over year · more shares

Price change (1Y)

-34.6%

Trailing year

Short interest

15.9%

Latest settlement · 9.4 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Neutral Momentum Very Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High

Market backdrop VIX 14.8 · calm Equity put/call 0.56

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg −30%

below

Price vs 50-day avg −14%

below

RSI (14) 37

neutral

MACD trend Positive

52-week position 2%

near low

Volume (OBV) Bullish div.

accumulating

Momentum

relative strength

Very Weak

1-month return −5%

trailing

6-month return −36%

trailing

YTD return −39%

this year

Relative strength −46%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $25 › 200d $31 — 200d above 50d

Institutional flow Distributing

4 of 200 funds reported for Sep 30 · net -26.3K sh shares

Insider flow Accumulating

Net +$186.0K over 90 days · 50% sells

Short interest Rising

15.93% of float · ▲ +21.6% MoM · 9.4 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

200 holders — near 3-yr high, broad support

Squeeze score 66

elevated · 0–100

Fundamentals

Fair

Revenue growth −51%

Y/Y

EPS growth +33%

Y/Y

Quant / Vol

risk profile

Very High

Volatility 55%

annualized · 1-yr

Max drawdown −49%

past year

ATR 6.0%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral

3 · 2 · 2

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−30% Bearish

Price vs 50-day avg

−14% Bearish

RSI (14)

37 Neutral

MACD trend

Positive Bullish

52-week position

2% Bearish

Volume (OBV)

Bullish div. Bullish

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $25 › 200d $31 — 200d above 50d

Institutional flow Distributing

4 of 200 funds reported for Sep 30 · net -26.3K sh shares

Insider flow Accumulating

Net +$186.0K over 90 days · 50% sells

Short interest Rising

15.93% of float · ▲ +21.6% MoM · 9.4 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

200 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $21 Now $22 · 2% Range high $41

vs 200-day avg -30% vs 50-day avg -14%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
NAMS NewAmsterdam Pharma Co N.V. this stock	$2.58B	-38.5%	-50.6%	—	15.9%
VRTX Vertex Pharmaceuticals Inc / Ma	$129.29B	+12.5%	+46.2%	29.7	1.8%
MRNA Moderna, Inc.	$89.83B	+663.0%	+4.3%	—	7.7%
REGN Regeneron Pharmaceuticals, Inc.	$76.86B	-3.3%	+20.8%	18.5	2.1%
CSLLY Csl Ltd	$61.83B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

197

% held: 105.2%
Reported: 4 of 200
Top holder: Frazier Life Sciences Man…

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Rising

Shares short

19.0M

Days to cover: 9.4d
Change: +3.4M sh

View

Short Volume

Short vol %

81%

As of: Oct 9, 2026

Short Total

View

Fails to Deliver

FTD shares

10.0K

Value: $256.8K
As of: Sep 9, 2026

View

Off-Exchange

Off-exchange %

46.1%

Week of: Aug 31, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net buying

Net (90d)

+$186.0K

Buyers / Sellers: 1 / 1

Buyers Sellers

View

Financials

Revenue (FY)

$22.5M

Net income (FY): $-203.8M
EPS diluted: $-1.72

View

Filings

SEC Filings

Latest

8-K

Filed: Sep 29, 2026
This year: 19

View

Proposed Sales

Value

$1.4M

Shares: 44.6K
Filed: Mar 11, 2026

View

Earnings & Events

Webcasts

Last webcast

Aug 5, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
NAMS	-7.0%	-5.4%	-36.2%	-11.3%	-38.5%
SPY	+1.2%	+1.9%	+9.9%	+2.1%	+14.2%
vs SPY	-8.2%	-7.2%	-46.1%	-13.4%	-52.7%

Key facts CIK 1936258 CUSIP N62509109 13F (30d) 3 filings 3 filers Visit website Investor relations

NAMS · NewAmsterdam Pharma Co N.V.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance